BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shah, N.
Right arrow Articles by wong, W. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shah, N.
Right arrow Articles by wong, W. L.

The British Journal of Radiology, Vol 73, Issue 869 482-487, Copyright © 2000 by British Institute of Radiology

ARTICLES

The impact of FDG positron emission tomography imaging on the management of lymphomas

N Shah, P Hoskin, A McMillan, P Gibson, J Lowe and WL wong
Department of Clinical Oncology, Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood, UK.

The role of 2-(F-18)-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) imaging in the management of patients with lymphoma has been evaluated. 29 patients (12 Hodgkin's disease, 17 non-Hodgkin's lymphoma (NHL)) who underwent FDG-PET imaging during their lymphoma treatment programme were reviewed retrospectively. Correlation between FDG-PET and CT was evaluated, together with the impact upon clinical management of the findings on FDG-PET imaging. FDG-PET added extra information to the findings on clinical examination and CT in 12 patients (41%). This was seen both in patients with negative and positive CT scan. Two false positive FDG-PET scans were seen, reflecting FDG uptake in extranodal sites. Information from FDG-PET imaging resulted in a change in clinical management in 10 patients (34%); in two, initial management was altered, and in eight consolidation therapy after completion of initial chemotherapy was influenced. These changes in clinical management occurred in six patients with high grade NHL, two with low grade NHL and two with Hodgkin's disease. No specific subgroup was identified in whom FDG-PET was particularly discriminant.


This article has been cited by other articles:


Home page
 Neuro OncolHome page
N. A. Mohile, L. M. DeAngelis, and L. E. Abrey
The utility of body FDG PET in staging primary central nervous system lymphoma
Neuro-oncol, April 1, 2008; 10(2): 223 - 228.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
E. Y. Tsai, A. Taur, L. Espinosa, A. Quon, D. Johnson, S. Dick, S. Chow, R. Advani, R. Warnke, S. Kohler, et al.
Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography.
Arch Dermatol, May 1, 2006; 142(5): 577 - 584.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. W. Friedberg and V. Chengazi
PET Scans in the Staging of Lymphoma: Current Status
Oncologist, October 1, 2003; 8(5): 438 - 447.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps
A Tabulated Summary of the FDG PET Literature
J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93.
[Full Text] [PDF]

Home page
 JNMHome page
G. M. Segall
FDG PET Imaging in Patients with Lymphoma: A Clinical Perspective
J. Nucl. Med., April 1, 2001; 42(4): 609 - 610.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2000 by the British Institute of Radiology.